Extracellular vesicles in chronic obstructive pulmonary disease (COPD)

Hannah E. O’Farrell¹, Ian A. Yang¹²

¹UQ Thoracic Research Centre, Faculty of Medicine, The University of Queensland, Brisbane, Australia; ²Thoracic Program, The Prince Charles Hospital, Metro North Hospital and Health Service, Brisbane, Australia

Contributions: (I) Conception and design: All authors; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: None; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Hannah E. O’Farrell. UQ Thoracic Research Centre, Room 2, Level 1 Clinical Sciences Building, The Prince Charles Hospital, Rode Road, Chermside, QLD, Australia. Email: hannah.ofarrell@uq.net.au.

Abstract: Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease characterised by chronic inflammation and significant airflow obstruction that is not fully reversible, and is one of the leading causes of morbidity and mortality worldwide. Extracellular vesicles (EVs) (including apoptotic bodies, microvesicles and exosomes) are small membrane-bound vesicles released by nearly all cell types and can be found in various bodily fluids including blood, sputum and urine. EVs are key mediators in cell-cell communication due to their ability to exchange information to recipient cells, influencing physiological and pathological conditions using their bioactive cargo (DNA, RNA, miRNA, proteins and other metabolites). Therefore the main aim of this review is to highlight recent evidence of the potential use of EVs as diagnostic and therapeutic biomarkers for COPD managements, as well as EVs potential role in COPD pathogenesis. As EVs have been under intense investigation as diagnostic and therapeutic biomarkers for lung disease, in relation to COPD, key studies have identified EVs as potential biomarkers to distinguish exacerbations from stable state, and to characterise COPD phenotypes. EVs are also linked to key inflammatory mediators in COPD progression. In addition, bacteria and their EV cargo influence the lung microenvironment. Further recent therapeutic approaches and advances have seen EVs bioengineered as novel drug delivery vehicles, which could potentially have clinical utility for lung diseases such as COPD.

Keywords: Extracellular vesicles (EVs); chronic obstructive pulmonary disease (COPD); biomarkers; therapeutics

doi: 10.21037/jtd.2019.10.16
View this article at: http://dx.doi.org/10.21037/jtd.2019.10.16

Introduction

COPD

Chronic obstructive pulmonary disease (COPD) is a preventable and treatable respiratory disease, which is characterised by persistent respiratory symptoms with significant obstruction of airflow that is not fully reversible and progressive, with features of chronic airway inflammation in the lungs in response to noxious particles or gases (1,2). Symptoms characteristic of COPD include exertional breathlessness, chronic cough, sputum production and exacerbations of COPD (1,2). COPD is one of the leading causes of morbidity and mortality worldwide, resulting in significant economic and social burden on society (3). In Australia a reported $929 million AUD ($629 million USD) per annum is spent on direct health expenditure attributed to COPD, significantly contributing to the health care burden (4). COPD is predicted to become the 3rd leading cause of death world wide by 2030 unless urgent action is taken to reduce underlying risk factors (5).

Exacerbations of COPD are defined as the worsening of symptoms above a patient’s usual baseline, which may require
pharmacological intervention and or hospitalisation (6). Patients who experience frequent exacerbations in one year will have a higher frequency in following years, considerably impacting on their quality of life (7).

As exacerbations are serious events that accelerate long-term decline in lung function and quality of life, it is important for more research to be undertaken to understand the pathogenesis of COPD exacerbations and underlying risk factors that can be modified through targeted preventive measures and interventions. In addition to developing a better understanding of environmental factors triggering exacerbations, further knowledge is needed about cellular and molecular processes involved in COPD exacerbations and disease progression. An increasingly important field of research relates to extracellular vesicles (EVs), which are produced by cells, and will be the focus of this review.

**EVs**

**Biogenesis**

Production of EVs is a universal feature of nearly all cells (8). These small enclosed vesicles can be detected in a variety of bodily fluids including blood, bronchoalveolar lavage fluid, tissue, urine, sputum and cell culture supernatant (9). EVs play a key role in cell-cell communication and exert their biological effects in a pleiotropic manner. They do this through direct vesicle membrane interaction with recipient cells, or deliver their bioactive cargo through recipient cell internalisation (10,11).

While EVs are all cell derived vesicles enclosed by a lipid bilayer, their biogenesis and secretion mechanisms distinguish them between 3 main classes, which include: apoptotic bodies, microvesicles and exosomes (**Figure 1**) (11). Apoptotic bodies are larger in size (1–4 µm) and are only formed during programmed cell death (10). Apoptotic bodies can contain non-coding RNAs, DNA fragments and cell organelles, and previous studies have suggested that genetic information can be transferred by the uptake of apoptotic bodies (10). Cell surface markers for apoptotic bodies include TSP and G3b.

Microvesicles (MVs) are smaller than apoptotic bodies, and larger than exosomes (100–200 nm) and are generated by the outward ‘budding’ of the plasma membrane releasing the nascent MV into the extracellular space membrane (12). MVs are heterogeneous and their function is determined by their bioactive cargo, which is dependent on their cell of origin from which they were shed (13). Once in the extracellular environment MVs cargo can influence the microenvironment through interaction with recipient cells (12). The release of MVs from the plasma membrane involves ARF1, ARF6 (members of the ADP-ribosylation factor small G-protein subfamily) and TSG101 [component of the endosomal-sorting complex required for transport (ESCRT)] (13).

Exosomes are nanosized vesicles (30–100 nm) and through intracellular endocytic invagination they are formed and released into the multivesicular body (MVB), generating intraluminal vesicles (ILVs) (14). During early to late endosome maturation, the MVB can then fuse with the plasma membrane, this allows exosomes bioactive cargo to be released into the extracellular space (15,16).

Enzyme neutral sphingomyelinase 2 (nSMase2) is essential in the formation of ILVs in the early endosome (14). The endosomal sorting complex required for transport (ESCRT) is required for ILVs to be delivered into MVBs (14). MVBs can then fuse with lysosomes for cargo degradation (ESCRT-dependent mechanism) or fuse with the plasma membrane, which releases the ILVs as exosomes using RAB GTPases (ESCRT-independent mechanism) (8,17). A number of different proteins can distinguish exosomes which include: tetraspanins, membrane transport and fusion proteins, raft proteins, MHC proteins and targeting/adhesion molecules, which can be found on exosomes surface membrane (8).

**Methods for EV isolation**

In order to study them, a number of methods are available for the isolation of EVs, each with their own advantages and shortcomings, which are important to consider in experimental planning. Traditional EV isolation methods utilize EV size and buoyant density through ultracentrifugation, microfiltration and gel filtration (18-20). Additional methods have since emerged based on EV solubility including precipitation with protamine, sodium acetate and polyethylene glycol (21-23). Recently isolation methods have appeared based on EV population-specific interactions with molecules on the EV surface as well as microfluidic technologies (20,24).

The International Society for Extracellular Vesicles (ISEV) has recommended guidelines for successful isolation and characterisation of EVs (25). It has been recognised that there is no optimal method for EV isolation, with current methods including size exclusion, immunoaffinity or ultracentrifugation. The most suitable method is therefore dependent on the scientific question proposed.
Figure 1 Biogenesis of extracellular vesicles in relation to COPD. Environmental factors including air pollution, noxious particles and bacterial/viral infections can influence the bioactive cargo delivered by EVs. EVs biogenesis begins through the formation of intraluminal vesicles inside MVBs which then bud into early endosomes through to late endosomes. MVBs will then fuse with the plasma membrane, causing the release of content into the extracellular space (exosomes) or through outwards budding and fission with the plasma membrane (microvesicles). Apoptotic bodies are formed during programmed cell death through actin-myosin mediated membrane blebbing. COPD, chronic obstructive pulmonary disease; EV, extracellular vesicle; MVBs, multivesicular bodies.
and if these methods are applicable with downstream experimental applications, and further that the method chosen is recorded in detail to ensure reproducibility (26). For EV characterization, ISEV has recommended that this is performed at the population and single vesicle level, involving positive and negative protein markers from four categories: (I) EV cytosolic protein, (II) transmembrane EV protein, (III) intracellular but not associated with plasma membrane proteins and (IV) extracellular but not typically associated EV proteins (25). Further to assess population heterogeneity, it is recommended that two complementary technologies are used such as electron microscopy paired with single particle tracking methods (25).

Due to EVs being potent packages of cell-cell communication through the transfer of their bioactive cargo, which reach various sites around the body, further influencing a variety of biological processes of recipient cells, this makes them ideal biomarkers for diagnostics and to investigate novel therapeutics (27), particularly for lung disease (Figure 1) (8). Therefore this review will now discuss how EVs and their cargo could have potential clinical utility as biomarkers and therapeutic agents for COPD disease management and treatment (a list of relevant studies for COPD EVs—some of which will be discussed in further detail below—can be found in Table 1).

The potential role of EVs in COPD pathogenesis

In normal lung physiology, EVs are likely to play a key role in maintaining homeostasis through intercellular communication in the human airway with studies reporting that lung epithelial cells are the main source of EVs in the lung (8,45). EV composition can be modified through external stimuli, further affecting EV secretion, and the influence EVs have on recipient cells and the surrounding lung microenvironment (8). Such modification may protect against harmful components from smoke exposure, DNA damage and infection (32,46). Studies have previously reported that detrimental immune responses are associated with stress-induced, lung-derived EVs, further contributing to the pathogenesis of chronic inflammatory lung diseases (47). An example is the release of exosomes from activated neutrophils that contain surface-bound neutrophil elastase, which is resistant to degradation by α1-antitrypsin, leading to excessive alveolar destruction (48).

One of the main causes of exacerbations in COPD patients are bacterial respiratory infections which contribute to disease progression through overproduction of mucus and defective mucociliary clearance in the airways (49). As most cells secrete EVs, when they are released during a pathogen infection they are able to reveal pathogen and host-derived factors, including their composition, origin and state of infection (50). Pathogen EVs play an important role in the regulation of the host’s immune response and pathogen uptake and replication (50). In order to promote pathogen survival, replication and pathology, bacterial and viral pathogens can disrupt exosome functions, through their interaction with intracellular transport and signalling pathways, further promoting infection and repressing host pathogen responses (50,51). EVs carrying pathogen-derived factors have potential as a diagnostic biomarker (50).

A study by Takahashi et al., identified that endothelial-derived MVs were significantly increased in stable COPD patients, which further increased in number during an exacerbation, compared to healthy individuals, highlighting the diagnostic potential for MVs to predict patients who are susceptible to exacerbations (29). Another study by Tan et al. assessed the expression levels of plasma exosomes in exacerbating and stable COPD patients and compared to a non-smoking healthy control patients. Results showed that plasma exosomes were significantly increased compared to controls and that exosome expression was associated with plasma CRP, sTNFR1 and IL-6, suggesting that exosomes are involved in the inflammatory process of COPD exacerbations (43).

EVs derived from Gram-negative bacteria [referred in literature as outer membrane vesicles (OMVs)], include molecules such as LPS, adhesion and invasion proteins to host cells, nucleic acids and immunomodulatory factors (52). Recently it was identified that Gram-positive bacteria also produce EVs, which was observed through transmission electron microscopy and proteomic analysis from Staphylococcus aureus and Bacillus subtilis cell culture supernatant (53). In mouse models bacterial-derived EVs have since been shown to induce neutrophilic pulmonary inflammation in a IL-17A dependent manner, and that this neutrophilic pulmonary inflammation which is involved in COPD pathogenesis and induced by E.coli EVs is further abolished when IL-17A is removed (37,54,55). In COPD patients, microbiomes in lung-derived EVs were found to be distinct from microbiomes characterised in lung tissue (42).

Additionally there is evidence to support that respiratory viruses have adapted to use EVs as transporters for viral particles and genomes for transmission and infection (56). In COPD, viruses are a common exacerbation trigger (57).
### Table 1 Key COPD EV studies over the past ten years

<table>
<thead>
<tr>
<th>Reference</th>
<th>EV type</th>
<th>Cohort</th>
<th>Main findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>(28)</td>
<td>Plasma endothelial microparticles</td>
<td>N=32 healthy non smokers, N=41 healthy smokers with normal spirometry and DLco, N=19 healthy smokers with normal spirometry and low DLco</td>
<td>This study found that smokers with emphysema have increased circulating EMPs, highlighting that monitoring plasma EMP levels would be useful for identifying early emphysema development</td>
</tr>
<tr>
<td>(29)</td>
<td>Plasma endothelial microparticles</td>
<td>N=80 stable COPD patients, N=27 exacerbation COPD patients, N=20 healthy non-COPD controls</td>
<td>This study showed that EMPs CD144+, CD31+ and CD62E+ were significantly elevated in stable COPD patients than healthy controls, further highlighting EMPs biomarker potential for COPD exacerbations</td>
</tr>
<tr>
<td>(30)</td>
<td>Macrophage microparticles</td>
<td>THP-1 macrophages or hMDMs with or without tobacco smoke extract exposure</td>
<td>Macrophage-derived EVs attributed to MMP14 were released in response to tobacco smoke extract exposure. Further these EVs may contribute to emphysema in smokers</td>
</tr>
<tr>
<td>(31)</td>
<td>Plasma endothelial microparticles</td>
<td>N=104 stable COPD patients, N=76 non-COPD patients</td>
<td>CD31+ EMPs were significantly elevated in mild COPD and emphysema patients compared to controls, while CD62E+ EMPs were significantly elevated in hyperinflation and severe COPD</td>
</tr>
<tr>
<td>(32)</td>
<td>Human mononuclear cell microparticles</td>
<td>Human mononuclear cells exposed to cigarette smoke extract with microparticles isolated</td>
<td>Macrophage EV release is increased by cigarette smoke extract through the activation of mononuclear cells via intracellular calcium mobilisation. These microparticles contain proinflammatory mediators</td>
</tr>
<tr>
<td>(33)</td>
<td>BALF EVs</td>
<td>N=8 mice (C57bl/6) per treatment group, saline control, LPS challenged, air exposed or smoke exposed BALF and lung tissue were collected</td>
<td>The results from this study support that infective agents (bacterial or viral) can trigger EV release in the airways of mice and humans and that ATP drives EVs to release IL-1β and IL-18 through a P2X7/caspase-1-dependent manner</td>
</tr>
<tr>
<td>(34)</td>
<td>Plasma endothelial microparticles</td>
<td>N=60 rats divided into six groups, containing 10 rats each. 3 groups of 10 rats were exposed to cigarettes for 2, 4 or 6 months, while the other 3 groups of 10 rats were control groups who were sham-smoked</td>
<td>Plasma CD42b-/CD31+ EMPs were significantly increased in rats exposed to cigarette smoke, highlighting their biomarker potential for pulmonary function impairment, which would be useful for evaluating COPD progression</td>
</tr>
<tr>
<td>(35)</td>
<td>Lung epithelial derived EVs</td>
<td>BEAS-2B human bronchial epithelial cells Primary human bronchial epithelial cells C57BL/6 mice (BALF fluid, lung tissue) Human lung tissue</td>
<td>BEAS-2B EVs increased in response to cigarette smoke extract, further inducing RAB27A, further inducing full length flICCN1 enriched EVs</td>
</tr>
<tr>
<td>(36)</td>
<td>Primary human bronchial epithelial cells (HBECs) EVs</td>
<td>BEAS-2B human bronchial epithelial cells EVs HBEC EVs Lung Fibroblasts used to assess EV uptake</td>
<td>HBECS-derived EVs promoted myofibroblast differentiation in lung fibroblasts in response to cigarette smoke extract. Further miR-210 derived from bronchial epithelial cells targeting ATG7 in lung fibroblasts leads to modulated autophagy</td>
</tr>
<tr>
<td>Reference</td>
<td>EV type</td>
<td>Cohort</td>
<td>Main findings</td>
</tr>
<tr>
<td>-----------</td>
<td>---------</td>
<td>--------</td>
<td>---------------</td>
</tr>
<tr>
<td>(37)</td>
<td>E. coli and dust derived EVs</td>
<td>WT C57BL/6, IFN-γ-deficient, IL-17A-deficient, or TNF-α-deficient mice</td>
<td>Neutrophilic inflammation and emphysema can be induced in a IL-17A dependent manner by E. coli-derived EVs, highlighting a novel target for COPD control</td>
</tr>
<tr>
<td>(38)</td>
<td>Plasma endothelial microparticles (EMPs)</td>
<td>N=28 non smokers, N=61 healthy smokers, N= 49 COPD smokers</td>
<td>COPD smokers and healthy smokers had elevated circulating EMPs compared to non smokers, which remained elevated over 12 months, but returned to non smoker levels for healthy smokers only who quit, unlike COPD smokers who quit with EMP levels still remaining significantly abnormal</td>
</tr>
<tr>
<td>(39)</td>
<td>Sputum microparticles</td>
<td>N=18 male COPD patients</td>
<td>Microparticles were able to be identified from sputum from COPD patients, with a negative correlation identified between FEV1 and CD31 MPs</td>
</tr>
<tr>
<td>(40)</td>
<td>Plasma endothelial microparticles</td>
<td>N=8 healthy non-smokers, N=17 COPD patients</td>
<td>miRNAs let-7d, miR-191; miR-126; and miR125a were significantly enriched in EMPs exposed to cigarette smoke, through the enzyme aSMase, which is significantly higher in COPD patient plasma</td>
</tr>
<tr>
<td>(41)</td>
<td>BAL EVs</td>
<td>N=10 smokers, N=10 non-smokers</td>
<td>BALs EVs from smokers and non-smokers were isolated, characterised and extracted for small RNAs containing miRNAs. RT-qPCR compared miRNA expression between the two groups. BEAS-2B cells were then exposed to BAL EVs to assess different miRNA expression between the two smoking groups. This is one of the first studies to show that smoking alters lung EV profiles in human samples, influencing surrounding bronchial epithelial cells</td>
</tr>
<tr>
<td>(42)</td>
<td>Lung tissue EVs</td>
<td>N=13 non smokers, N=13 healthy smokers, N=13 COPD patients</td>
<td>This study showed that lung tissue EVs contained more operational taxonomic units (OTUs) than lung tissue. Lung tissue EVs in healthy smoker and COPD groups contained higher Shannon index and lower Simpson index compared to lung tissue. Firmicutes in the EV COPD group compared to other groups was highly present</td>
</tr>
<tr>
<td>(43)</td>
<td>Plasma exosomes</td>
<td>N=20 Exacerbation COPD patients, N=20 Stable COPD patients, N=20 Healthy aged matched controls</td>
<td>Circulating plasma exosome levels (CD9+) were significantly higher in COPD patients compared to healthy controls, with the level of exosomes correlating with systemic inflammatory markers CRP, sTNFR1 and IL-6. This study highlights exosomes involvement in COPD and that they may mediate inflammatory processes</td>
</tr>
<tr>
<td>(44)</td>
<td>Bronchial epithelial cell EVs</td>
<td>N=5 COPD stable patients, N=5 healthy controls—serum was collected</td>
<td>Serum EVs had elevated miR-21 in COPD patients. Further BEAS-2B EVs when exposed to cigarette smoke extract produced less miR-21, having a reduced impact on M2-directed macrophage polarisation in comparison to control EVs</td>
</tr>
</tbody>
</table>

EV, extracellular vesicle; COPD, chronic obstructive pulmonary disease.
Viruses exploit EV machinery to uptake virus-expressed molecules (such as virions, proteins, mRNAs and miRNAs) in exosomes (50,58), which can then be transferred to uninfected recipient cells through a number of mechanisms, including interaction with the ESCRT pathway, as well as viruses utilising the Ras-related protein Rab pathway (50).

Recently EV based vaccines using pathogen EVs and their bioactive cargo have shown promising results (59-61). Clinical trials assessing OMVs have been advantageous compared to conventional vaccines against infectious diseases, as unlike cell and virus therapies, EVs cannot multiple or divide, suggesting they are therefore safer and less tumorigenic and infectious (62). Risks such as pathogen co-isolation with EVs has been considered, which is particularly relevant for viruses, who have similar biophysical properties to EVs (63). Overall EV-based vaccines used as antimicrobial treatment in preclinical and clinical trials has so far been reported to be well-tolerated and feasible, however further validation in humans is needed to show consistent immunostimulatory therapeutic effect (63).

**Circulating miRNAs and EV miRNAs as potential COPD biomarkers**

Biomarkers are clinical features that reflect disease activity and fluctuate with disease state, making them useful for diagnosis, monitoring of disease progression, as well as response to therapy (64,65). EVs have been identified as novel disease biomarkers due to their ability to reflect their parent cells physiological state and microenvironment, as well as being highly stable in circulating bodily fluids, due to their phospholipid bilayer, and have the ability to package an array of disease associated biomolecules, overall making them strong biomarker candidates.

microRNAs (miRNAs) are short non-coding RNAs that regulate gene expression post-transcriptionally (66). miRNAs have been shown to be stable in a variety of body fluids, including saliva, sputum, urine, breast milk and blood (66). Specific miRNAs are have been demonstrated to be selectively exported into EVs, while others are excluded (67). The mechanisms behind this are complex but studies have demonstrated miRNA sorting into EVs through the RISC complex loading miRNAs into the multivesicular bodies (68), sumoylated heterogenous nuclear ribonucleoprotein A2B1 (69) and Annexin A2 (70). Given the transportability of vesicles, the role of which miRNAs are that packaged into EVs during different disease states is gaining increasing attention. Based on recent studies, miRNAs are differentially enriched in EVs, and in respect to different lung diseases, their expression can change, further altering recipient cells biological processes and overall disease pathophysiology (71).

A number of studies have reported various circulating miRNAs that are involved in the development and progression of COPD, including emphysema severity (72) [lists of studied circulating miRNAs have been extensively detailed in previous reviews (73,74)].

Recent studies investigating exosomal miRNA expression include a study by Fujita el al, who reported that intercellular crosstalk and COPD pathogenesis were modulated by miRNAs through EV-mediated miRNA transfer (36). Specifically, miR-210 expression was significantly increased in bronchial epithelial cell (BEC)-derived EVs as well as BECs after cigarette smoke exposure, promoting airway fibrosis in COPD pathogenesis (36). Another study investigating EV transfer of miRNAs in COPD pathogenesis reported microparticles were secreted on the ceramide-synthesis enzyme sphingomyelinase (aSMase), which induced the release of select miRNAs including miR-191, miR-126 and miR-125a, to be transferred to macrophages, promoting the clearance of apoptotic cells (40). Exosomal miR-21 derived from bronchial epithelial cells has also recently been found to be responsible for myofibroblast differentiation in response to cigarette smoke, with exosomal miR-21 levels found to be high in the sera of smokers and COPD patients (75).

Due to the differential changes in plasma mRNAs, exosomal miRNAs are therefore not equivalent to the measurement of circulating miRNAs (76). Therefore future studies looking into exosomal miRNAs can be useful to extend previous reports of circulating miRNAs with biomarker potential, for example, by identifying if both miRNA levels of plasma and plasma exosomes are similar.

**Therapeutic potential of EVs in COPD**

**EVs as cargo delivery vehicles**

The utility of EVs, in particular exosomes as a diagnostic marker for diseases and potential for therapeutic intervention, is currently under intense investigation. One of the first considerations for developing an EV therapeutic is the cellular source. Mesenchymal stromal cells (MSCs) have been reported to be anti-inflammatory and regenerative and pre-clinical trials have been undertaken using MSCs for the treatment of COPD (77-79). However
there is still no evidence for clinically relevant effects and further study of MSC-based treatments for COPD patients is needed (79). Efforts have increased in the development of MSC-EVs as a potential therapeutic, with studies reporting that the immune-regulatory function and regenerative capacity of MSCs is mimicked in their EVs (80-82). Issues such as culture conditions, yield, manufacturability and working with mammalian cell EVs themselves, have been addressed by research groups who have reported using EVs derived from fruits and vegetables, as they are able to be loaded with small molecular cargo, which can mediate a therapeutic effect in animal models (83-85). Another consideration for EV therapeutics is the route of administration for use in patients (86).

EVs can be modified for therapeutic use through molecular engineering techniques. Two basic approaches can be utilized to modify EVs for therapeutics: (I) exogenously, which involves incorporating therapeutic cargo (small molecules/proteins or RNAs) into or onto isolated EVs, or (II) endogenously, which involves providing cells with the means to incorporate therapeutic cargo into EVs during their biogenesis (63). Exogenous methods to package therapeutic cargo into EVs occurs after EV collection by co-incubation, electroporation and sonication (87-89). This has proved successful in studies that incubated EVs with curcumin, which improved anti-inflammatory and bioavailability of this drug in an inflammation mouse model (90). Endogenous methods for loading therapeutic cargo involve genetically modifying parental cells to over express target RNA or protein of interest, which is then naturally taken up and secreted by EVs (63). Similar methods can be used as exogenous EV loading such as incubation, transfection and or transduction (91-93). A novel study by Alvarez-Erviti et al. delivered siRNAs targeting housekeeping genes and a therapeutic target for Alzheimer’s disease using exosomes into mouse brains, using electroporation as a method of transfection (88). Another study by Zhang et al. used a novel protocol to manipulate exosomal miRNAs with high efficiency and successfully deliver them to recipient cells (94). Through the modification of a calcium chloride transfection method, miRNA mimics and inhibitors were enhanced, further allowing the direct transfection of exosomes instead of transfection of mother cells (94).

A number of studies that have investigated the role that EVs play in disease pathogenesis has shed light on their use to deliver cell specific therapy as cargo (95,96). It has been reported that for exosome loading, miRNAs are not randomly selected, with exosomes enriched in 3’-UTR RNA fragments being more likely to be sorted into exosomes (69,97). EVs protect miRNAs from digestion and degradation through shuttling and evasion of immune system surveillance due to EVs carrying the same surface proteins as their cell of origin (98). This further highlights the utility of EVs as a mediated small nucleotide delivery system (94).

In order for EV-mediated miRNA delivery to be used as a treatment therapy, several issues still need to be addressed. This includes overcoming miRNA enrichment into EVs, as well as assessing EV shuttling miRNAs physiological and pathological effects on recipient cells (94). Studies have reported that the load of miRNAs from tumour cells are low in individual exosomes from patient plasma, and that host-derived exosomes are unable to deliver a sufficient copies of desired miRNAs without their composition being manipulated (99). However one of the benefits of using host/patient serum circulating exosomes is the high cell specificity and less likely chance to cause a reaction or rejection by the recipient (94).

Another additional consideration is the use of EVs to transfer bioactive cargo targeting gene replacement or inhibiting expression of inherited diseases (63). Adeno-associated vectors (AAVs) are a novel gene therapy tool that has shown promising results in clinical trials (100). Further a study by Maguire et al. was able to overcome limitations associated with using AAVs through the use of their associated EVs (exo-AAVs), which were found to be superior to AAVs, in neutralising anti AAV antibodies in vitro and in vivo, as well as transduction efficiency (101). The use of exo-AAV as a novel gene delivery system may holds clinical potential for the treatment of genetic disorder alpha-1 antitrypsin deficiency, which can lead to emphysema and COPD.

Therapeutic potential for probiotic EVs

Probiotics are defined as “live organisms, which when applied in adequate amounts confer a health benefit to the host” (102). Probiotic Lactobacillus is a Gram-positive facultative anaerobic bacteria and considered non-pathogenic (103,104), with reported benefits such as inhibiting cytokine-induced apoptosis, as well as decreasing the pathogenicity of other pathogens such as E.coli (105,106).

EVs are able to influence their host through a variety of cellular responses, which proves essential for bacteria to communicate with host cells as a layer of mucin prevents...
physical contact between host tissue and bacteria (107,108). EVs also have the potential to mediate therapeutic molecule delivery without inducing adverse immune reactions (107). Therefore the EVs produced by probiotic bacteria may exert a positive effect in stabilising dysbiosis in the lung microenvironment, further increasing treatment efficacy.

Studies investigating the bacterial microbiome in lung tissue have reported that the bacteria *Lactobacillus* is unique to severe COPD patients (GOLD stage 4) in comparison to smoking and non-smoking control groups (109). A study by Sze et al. reported that the loss of GD1 (glycerol dehydratase gene), most commonly found on plasmids with *Lactobacillus reuteri*, results in increasing COPD severity and that GD1 holds anti-inflammatory properties, highlighting *Lactobacillus* potential as a possible therapeutic (110).

Further, work investigating probiotic conditioning of *C. elegans* with *Lactobacillus* derived EVs reported protection against VRE (vancomycin-resistant enterococci, an antibiotic resistant bacterium) infection, highlighting that EVs produced by this bacterium up regulate the expression of host defence genes and exert a protective effect on the host. This study supports that the use of probiotic-derived EVs, and not just the probiotic bacteria, is a novel therapy to treat antimicrobial-resistant pathogens (111).

**Future directions**

The clinical efficacy of EV cargo transfer for treating disease has previously been undertaken in phase 1 and 2 trials for a number of diseases [as previously described in detail (63)]. For non-small cell lung cancer (NSCLC), tumour antigen-loaded DC-derived exosomes were found to be well-tolerated by patients and safe for treatment, boosting antitumor immunity (112). Another study using MSC-derived exosome therapy has been found to reduce symptoms of steroid-refractory graft vs. host disease with no noticeable side effects (113).

Overall issues that still need to be addressed for future implementation of EVs as a diagnostic or therapeutic tool into clinic are a more standardised protocol for EV isolation, particularly which population of EVs is being investigated, and if the bioactive cargo specific to disease status is directly being identified from this specific EV population and not just extracellular content. Additional considerations include the mechanisms behind EV bioactive cargo incorporation and packaging, as well as the mechanisms behind recipient cells uptake EVs and their bioactive cargo.

**Conclusions**

COPD is a heterogeneous disease, characterised by airway inflammation, destruction of lung tissue and airflow limitation associated with airway remodelling. Exacerbations are a major cause of disease progression, morbidity and mortality and given the lack of curative treatments, new diagnostic and therapies for COPD are highly relevant. EVs are highly stable and potent packages of cellular information, and are able to exchange their bioactive cargo to recipient cells around the body, influencing physiological and pathological conditions. Furthermore EVs have significant therapeutic potential due to their ability to be manipulated and engineered to be used as targeted diagnostic and therapeutic tools. This review has highlighted recent evidence of the potential of EVs as biomarkers, and how this could be applied specifically for COPD management. Future studies investigating bioengineered EVs and their use as novel drug delivery vehicles hold great promise for therapeutic translation into the clinic.

**Acknowledgments**

**Funding:** The Prince Charles Hospital Foundation (HO, IY), NHMRC project grant APP1121740 (IY), The University of Queensland PhD scholarship (HO).

**Footnote**

**Conflicts of Interest:** The authors have no conflicts of interest to declare.

**Ethical Statement:** The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**References**


56. Altan-Bonnet N. Extracellular vesicles are the Trojan horses of viral infection. Curr Opin Microbiol 2016;32:77-81.


97. Batagov AO, Kurochkin IV. Exosomes secreted by human cells transport largely mRNA fragments that are enriched in the 3’-untranslated regions. Biol Direct 2013;8:12.